

Published in final edited form as:

Semin Immunol. 2013 December 15; 25(6): 469–484. doi:10.1016/j.smim.2013.10.008.

Treating inflammation by blocking interleukin-1 in humans

Charles A. Dinarello^{a,b,*} and Jos W.M. van der Meer^b

^aDepartment of Medicine, University of Colorado Denver, Aurora, CO, United States ^bDepartment of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Abstract

IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL-1-mediated inflammation. Although IL-1, either IL-1 α or IL-1 β , was administered to patients in order to improve bone marrow function or increase host immune responses to cancer, these patients experienced unacceptable toxicity with fever, anorexia, myalgias, arthralgias, fatigue, gastrointestinal upset and sleep disturbances; frank hypotension occurred. Thus it was not unexpected that specific pharmacological blockade of IL-1 activity in inflammatory diseases would be beneficial. Monotherapy blocking IL-1 activity in a broad spectrum of inflammatory syndromes results in a rapid and sustained reduction in disease severity. In common conditions such as heart failure and gout arthritis, IL-1 blockade can be effective therapy. Three IL-1 blockers have been approved: the IL-1 receptor antagonist, anakinra, blocks the IL-1 receptor and therefore reduces the activity of IL-1 α and IL-1 β . A soluble decoy receptor, rilonacept, and a neutralizing monoclonal anti-interleukin-1 β antibody, canakinumab, are also approved. A monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1 α are in clinical trials. By specifically blocking IL-1, we have learned a great deal about the role of this cytokine in inflammation but equally important, reducing IL-1 activity has lifted the burden of disease for many patients.

Keywords

Autoimmune; Autoinflammatory; Inflammation

1. Introduction

The importance of IL-1 as a master cytokine in inflammation comes from infants born with a loss of function mutation in the naturally occurring endogenous IL-1 receptor antagonist (IL-1Ra). IL-1Ra blocks the IL-1 receptor type 1 (IL-1R1), which is on all cells; therefore, systemic inflammation may come from either IL-1 α or IL-1 β . These infants succumb early in life with overwhelming sterile inflammation of the skin, joints and bone with large numbers of infiltrating neutrophils and high levels of interleukin-17 [1,2]. The condition is called deficiency of interleukin-1 antagonist (DIRA) and daily treatment with anakinra rapidly reverses the inflammation and prevents a fatal outcome. Mice deficient in IL-1Ra are similarly affected in that these mice develop spontaneous inflammation such as a rheumatoid arthritis-like disease and can succumb to lethal arteritis. The best evidence for a role for either IL-1 α or IL-1 β in disease comes from specific blockade, as correlations of

circulating levels and disease severity are not informative and do not establish causality. Even in the most severe IL-1 β -mediated autoinflammatory diseases, IL-1 β levels in the circulation increase only by factor of five [3].

There are two IL-1's. IL-1 α is expressed as a precursor and is constitutively present in most cells of healthy subjects. The cytokine is found in normal keratinocytes of the skin, the epithelial cells of mucosal membranes throughout the body and the cells of organs such as the liver, lung and kidney. Platelets also contain IL-1 α . The entire endothelium of the vasculature contains the IL-1 α precursor and in membrane fragments from the endothelium termed "apoptotic bodies" [4]. These membrane fragments are active in inducing neutrophil infiltration [4] in several inflammatory conditions of the blood vessels termed vasculitis [5]. During ischemia, however, cell death by necrosis takes place and the IL-1 α precursor is released [6,7].

In contrast, IL-1 β is not present in health or at levels not detected by standard assays. IL-1 β is a product of blood monocytes, tissue macrophages and dendritic cells. The rate-limiting step in the production of IL-1 β is transcription, but IL-1 β mRNA requires an additional signal for synthesis. The stimulus can be a microbial product but cytokines, such as TNF α , IL-18, IL-1 α or IL-1 β itself induce IL-1 β [8]. In fact, IL-1 induction of itself is part of the mechanism of "autoinflammation". IL-1 β is first synthesized as an inactive precursor but the precursor requires cleavage by caspase-1, an intracellular cysteine protease. Caspase-1 itself requires activation in order to process IL-1 β into an active cytokine. The activation of caspase-1 proceeds following the oligomerization of a complex of intracellular proteins termed the "inflammasome" by the late Tschopp [9,10]. With activation of caspase-1, the N-terminal amino acids are cut and mature IL-1 β is readily secreted as an active cytokine. One of the components of the inflammasome termed "cryopyrin" (also termed NLRP3) plays a critical role in the secretion of IL-1 β . A single amino acid mutation in cryopyrin [11] results in enhanced caspase-1 activity and greater secretion of IL-1 β . Increased production and secretion of IL-1 β from blood monocytes is characteristic of a group of autoinflammatory diseases termed "cryopyrin associated periodic syndrome (CAPS)".

2. Autoinflammatory diseases are different from autoimmune diseases

Autoinflammatory diseases are chronic, debilitating syndromes [12]. As stated above, some autoinflammatory conditions are due to mutations in the intracellular proteins that control caspase-1, the enzyme that converts IL-1 β to an active cytokine prior to release from the cell. Although these conditions are rare, the inflammatory manifestations are common to many diseases. Blood monocytes from patients with autoinflammatory diseases release more IL-1 β compared to cells from healthy persons [13–17]. In autoimmune diseases, however, dysfunctional T-lymphocytes are fundamental to pathogenesis. Autoimmune diseases such as rheumatoid arthritis, Crohn's inflammatory bowel disease and plaque psoriasis are effectively treated with an expanding number of anti-cytokine-based therapies, depleting antibodies and inhibitors of cell migration [18]. Of these, agents to block tumor necrosis factor-alpha (TNF α) are used widely.

In contrast, classic autoinflammatory diseases are uniquely responsive to IL-1 β blockade whereas neutralization of TNF α is not effective or can exacerbate the condition. Neutralization of TNF α in gout and in Type 2 diabetes, which are responsive to IL-1 blockade, is without effect. One explanation is that TNF α is not the dominant cytokine produced in the gouty joint [19] nor the insulin-producing pancreatic islet cells [20]. Whereas in autoinflammatory diseases, the release of IL-1 β from the monocyte is elevated, but in the same cells the production of TNF α is not different from that of healthy controls.

3. Treating a broad spectrum of inflammatory conditions with anakinra

The IL-1 receptor is expressed in nearly all tissues and thus anakinra provides an optimal therapy, as the antagonist prevents the binding of either IL-1 α or IL-1 β . However, how much of the efficacy of anakinra is due to blocking IL-1 α and how much is due to blocking IL-1 β ? The amount of IL-1 β that circulates in IL-1-mediated inflammatory conditions is in the low nanogram range [3]; IL-1 α is rarely found in the circulation. Therefore, the use of anakinra has provided the data on the role of IL-1 in a broad spectrum of inflammatory diseases. Table 1 summarizes the joint, bone and muscle diseases, in which anakinra is effective. Some are large studies of randomized and placebo controlled trials such as rheumatoid arthritis whereas others are smaller studies and several are single case reports. Characteristically of the case reports are treatment benefits by anakinra in patients refractory to standards of therapy, such as often high doses of glucocorticoids, methotrexate and anti-TNF α based therapies.

4. IL-1 and acute onset diseases

IL-1-mediated inflammation contributes to catastrophic events such acute lung injury, myocardial infarction, acute kidney failure and stroke with end organ failure. There is no dearth of animal studies demonstrating an essential role for IL-1 following an ischemic injury of the heart [21], lung [22], liver [23], kidney [24] and brain [25] (Fig. 1). Inflammation following an ischemic event is characterized by infiltration of neutrophils and myeloid precursors into the surrounding ischemic area, often termed the penumbra (Fig. 2). For example, occlusion of a cerebral blood vessel results in necrotic brain tissue surrounded by a penumbra of healthy cells with infiltrating inflammatory cells. The area of gross necrosis is replaced by scar and loss of function; however, the cells in the penumbra of inflammation are salvageable by blocking IL-1. In fact, reducing IL-1 activity with anakinra has been tested in ischemic stroke patients and shown to be beneficial [26].

5. Blocking IL-1 in heart disease

5.1. Post-infarction cardiac remodeling

Based on a large number of animal studies, blocking IL-1 in humans with heart disease has entered clinical medicine [27]. Anakinra has been used successfully in patients with ST-elevation myocardial infarction (STEMI) [28] and repeated in a second trial [29]. Both trials were randomized and placebo controlled. STEMI has a high risk of death but patients who survive the acute event often progress to chronic heart failure due to loss of viable myocardium. In the first randomized, placebo-controlled trial of patients with STEMI, daily anakinra was added to standard of therapy the day after angioplasty and continued for 14 days. Serial imaging and echocardiographic studies were performed 90 days following the infarction. Left ventricular remodeling was significantly reduced with anakinra treatment compared to placebo-treated patients [28]. Moreover, the improvement with anakinra correlated with reductions in C-reactive protein (CRP). CRP is a large protein produced by the liver in response to any infectious or inflammatory condition. It is commonly measured in the circulation as a marker of the severity of inflammation, particularly in patients with coronary artery disease. After 18 months, 60% of placebo-treated patients had developed heart failure whereas none developed in the anakinra-treated patients. In the second, expanded trial, similar findings were observed, although the more severe the infarction, the greater the benefit of anakinra [29]. When the data were pooled with those from the first trial ($n = 40$), 5% of patients randomized to anakinra developed heart failure whereas 30% were affected in the placebo arm ($p = 0.035$) [29].

5.2. Heart failure

Despite several treatment regimens, heart failure continues to be a major medical problem with significant economic and social burdens. Poorly compensated patients with left ventricular ejection fraction less than 40% and elevated serum CRP greater than 2 mg/L were treated with anakinra and subjected to controlled exercise performance testing. Physiologically, after 14 days of anakinra, oxygen consumption increased significantly from baseline, carbon dioxide retention decreased and exercise performance improved [30]. Serum IL-1 β levels fell by 89%, CRP by 88% and IL-6 by 90%, but there was no change in levels of TNF α [30]. Since IL-1 β induces IL-6, a fall in IL-6 is indicative of a decrease in the biological activity of IL-1 itself, supporting the concept that heart failure is an autoinflammatory disease.

These data in humans with heart failure are similar to rheumatoid arthritis patients who were treated for 30 days with anakinra during which time left ventricular function improved [31]. In a related study, a single subcutaneous dose of anakinra resulted in increased blood flow 3 h later [31]. Overall, these improvements in heart function are also consistent with previous studies in human atrial heart strips *ex vivo* in that IL-1 suppresses contractile force [32] and that blocking IL-1 restores decreased function after ischemia-reperfusion [33]. Several animal models show that IL-1 suppresses the myocardium (reviewed in [30]). With only a 14-day course of anakinra in patients receiving current treatment standards, a greater duration of blockade may result in a greater return of function.

Although heart failure is often associated with decreased left ventricular ejection volume, some 50% of patients with hemo-dynamically defined heart failure have normal left ventricular systolic function but with impaired left ventricular diastolic filling. This type of heart failure is also called diastolic heart failure and patients with rheumatoid arthritis exhibit signs of this form of heart failure. Moreover, anakinra treatment of rheumatoid arthritis patients with heart failure restored left ventricular diastolic function [31]. In a double-blind, placebo-controlled, cross-over trial, patients received 14 days of anakinra 100 mg per day or placebo. Before and after the treatment schedules, exercise testing was performed. Anakinra resulted in improved peak oxygen consumption ($p = 0.009$) and a 75% decrease in CRP [34]. For patients with rheumatoid arthritis and the co-morbidity of diastolic heart failure, anakinra treatment for the arthritis would provide an improved treatment option since no other anti-cytokine treatment for rheumatoid arthritis reduces heart failure, and in the case of TNF blockers, there is a risk for patients with heart failure.

6. Diabetes

6.1. Type-1 diabetes

In 1986, the Danish scientists Mandrup-Poulsen and colleagues published their findings that picomolar concentrations of IL-1 β were selectively toxic for the insulin-producing pancreatic beta-cell (reviewed in [35]). These studies resulted in a paradigm change for the pathogenesis of Type-1 diabetes in that a macrophage product rather than a cytotoxic T-cell became the target for salvaging the beta-cell. In the non-obese diabetic mouse strain, the *sine qua non* model for Type-1 diabetes, IL-1 blockade reduces spontaneous diabetes [35] but also in a rat model of spontaneous diabetes [36]. After 25 years of research on IL-1 in diabetes, trials of IL-1 blockade have begun.

In a 28-day long trial of anakinra in children within one week of the onset of diabetes, insulin use after one and four months from diagnosis were significantly lower compared to historical controls [37]. Repeated courses of IL-1 blockade will likely be needed to suppress ongoing IL-1-mediated islet inflammation. However, chronic use of anakinra or canakinumab appears safe in children with autoinflammatory diseases [38,39]. How does the

likelihood of repeated courses of an IL-1-blocking therapy compare to other therapies in Type-1 diabetes? Immunosuppressive agents such as cyclosporine arrest the progression of the autoimmune process in children with Type-1 diabetes [40], but at a cost of unacceptable risk [41] compared to daily insulin. More recently, anti-CD3 monoclonal antibodies that deplete T-cells [42] and an anti-CD20 B-cell depleting antibody [43] result in increases in serum C-peptide levels, a validated biomarker of improved beta-cell function. However, these depleting antibodies have limitations for continued treatments and carry the risk of progressive multifocal leukoencephalopathy, a fatal brain disease. Repeated courses of anakinra, on the other hand, could keep islet inflammation at bay, reduce episodes of dangerous low blood sugar and increase insulin sensitivity [44].

Two randomized, placebo controlled, double-masked trials of anakinra and canakinumab monotherapy in new-onset diabetes have been completed [45]. In the anakinra trial, subjects with newly diagnosed (within 3 months) Type-1 diabetes received 100 mg of daily subcutaneous anakinra or placebo for 9 months. The primary endpoint is beta-cell function assessed as C-peptide response to a standardized 2-h mixed-meal challenge. Secondary endpoints include insulin requirement, percent insulin-free remission, and 2-h glucose levels after an oral glucose load. In the canakinumab trial, treatment began within 3 months of diagnosis, subjects received either monthly subcutaneous injections of 2.0 mg/kg canakinumab or placebo for 12 months. All groups received standard intensive diabetes treatment with insulin and dietary management and followed for 1–3 years. The primary endpoint was levels of C-peptide following a mixed-meal test after one year of canakinumab or placebo treatment. There was no significant difference in C-peptide levels between either anakinra or canakinumab and the respective placebo arms [45]. However, in the anakinra trial, there was a statistically significant difference ($p = 0.006$) between anakinra and placebo when assessed by three categorized levels of C-peptide [45]. The authors of these studies suggested that a combination of IL-1 blockade plus targeting T-cells may be needed to arrest the loss of beta cells in Type 1 diabetes.

6.2. Type-2 diabetes

Studies of the role of IL-1 β in the pathogenesis of Type-2 diabetes reported that high concentrations of glucose stimulated IL-1 β production from the beta-cell itself [46], thus implicating a self-destructive role of IL-1 β autoinflammation by the beta-cell (reviewed in [20]). Moreover, IL-1 β increases the deposition of amyloid, which contributes further to beta-cell loss [47]. Indeed, gene expression for IL-1 β is one hundred-fold higher in beta-cells from Type-2 patients [20] compared to non-diabetic patients. Thus, in Type-2 diabetes there is progressive loss of the beta-cell due to IL-1-mediated inflammation, which may also underlie the mechanism of insulin resistance [44].

Clinical proof of a role for IL-1 in the pathogenesis of Type-2 diabetes can be found in the randomized, placebo controlled study of anakinra for 13 weeks, in which there was improved insulin production and glycemic control associated with decreased CRP and IL-6 levels [48]. Unexpectedly, in the 39 weeks following the treatment, anakinra responders used 66% less insulin to obtain the same glycemic control compared to baseline requirements [49]. This observation suggests that blocking IL-1 β , even for a short period restores the function of beta-cells or possibly allows for partial regeneration. These findings of anakinra treatment in Type-2 diabetic have been confirmed using anti-IL-1 β monoclonal antibodies: Xoma gevokizumab [50], Novartis canakinumab [51] and Lilly LY2189102 [52]. Gevokizumab treatment also reduced the fatigue in Type-2 patients [53], as did anakinra in Sjogren syndrome [54]. Anakinra has also been tested in obese non-diabetic patients with metabolic syndrome [44]. There was a decrease in CRP and circulating leukocytes; the

disposition index increased significantly after anakinra treatment, reflecting improved beta-cell function [44].

Thus, Type-2 diabetes emerges as a chronic inflammatory disease, in which IL-1 progressively destroys the insulin-producing beta-cells or renders the beta cell non-functional [20]. The IL-1 β can come from the beta-cell itself, but also from blood monocytes that infiltrate the islet. Obesity is a high risk for Type-2 diabetes and caspase-1 dependent IL-1 β production has been demonstrated in macrophages isolated from human fat [55]. IL-1 α and IL-1 β exert the same toxic effect on the insulin-producing beta cells and it is unclear to what extent IL-1 α plays a role in humans with Type-2 diabetes. A neutralizing anti-human IL-1 α will test a role for IL-1 α in Type-2 diabetes.

6.3. Cardiovascular events in Type-2 diabetes

A large body of pre-clinical data reveals that IL-1 plays a role in the progression of atherosclerosis [56–58]. Because Type-2 diabetes increases the risk of cardiovascular events, blocking IL-1 β activity in these patients may also reduce the incidence in myocardial infarction and stroke. The largest trial of an anti-cytokine is CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) testing whether canakinumab will reduce cardiovascular events in Type-2 diabetics with high CRP levels despite optimal statin therapy [59]. The rationale for CANTOS is based on the consistent decrease in CRP levels observed with anakinra [48], canakinumab [60] or gevokizumab [50].

7. Arthritis and joint diseases

7.1. Rheumatoid arthritis

Anakinra has been studied in several controlled studies in patients with rheumatoid arthritis with and without methotrexate (reviewed in [61]) (Table 1). Overall, each study revealed a statistically significant reduction in disease severity, improvement in quality of life and a decrease in radiographic evidence of joint space narrowing. Because of the half-life of 6 h, daily injections of anakinra are required. The subcutaneous injections can produce injection site reactions, although these usually resolve within 14 days. In patients failing TNF α blockers or for whom TNF α blockers are contraindicated, anakinra is effective in controlling disease activity. There is no controlled head to head comparison of the outcome of an IL-1 blocking therapeutic to one of the growing list of biologics presently used for rheumatoid arthritis. However, after one year of anakinra therapy alone or in combination with methotrexate, improvements seem to be similar to those of the other biologics [62–66].

Compared to anakinra, TNF α blockers dominate the field of biologics for rheumatoid arthritis. One explanation for the popularity of TNF α blockers is the often-described sense of well-being experienced by patients within hours of treatment. Using functional magnetic resonance imaging, antibodies to TNF α blunt pain receptors in the brain within minutes of an intravenous infusion [67]. This property likely contributes to the rapidity of efficacy in clinical outcome scores by reducing disease-associated pain, fatigue and depression. Similar to anakinra, canakinumab has reduced disease severity in new onset rheumatoid arthritis patients, including patients who fail anti-TNF α therapies [68]. However, canakinumab trials have been suspended in rheumatoid arthritis trials perhaps due to the increasing number of agents competing for the same market. Unlike anakinra, the long-term benefit of preservation of joint function with canakinumab remains unstudied.

7.2. Crystal arthritis: gout and calcium pyrophosphate crystal arthritis

Patients with recurrent attacks of gouty arthritis unable to use colchicine and other standards of therapy often require steroids to control disease flares. When treated with anakinra (Table

4), canakinumab (Table 5) or rilonacept (Table 6), a rapid, sustained and remarkable reduction in pain as well as objective signs of reduced inflammation have been observed [69–79]. The effect of IL-1 blockade appears to be superior to that of steroids and result in prolonged periods without flares. The likely mechanism for urate crystal-induced IL-1 is in combination with free fatty acids, which accounts for nutrition-related flares of gout [80]. Given the characteristic neutrophilic infiltration in gouty joints, it is also likely that the IL-1 β precursor is processed extracellularly by neutrophilic enzymes [81]. Pyrophosphate crystal arthritis is highly responsive to anakinra [71,77].

7.3. Osteoarthritis

In humans, subcutaneous anakinra improved pain and swelling in an aggressive form of erosive osteoarthritis [82]. Anakinra has also been injected intraarticularly in patients with knee osteoarthritis [83,84], but the benefit did not extend beyond one month [84], which may be due the brief duration in the joint space. Systemic treatment of osteoarthritis with an antibody to the IL-1 receptor was carried-out and a modest improvement was reported, particularly in those patients with high pain levels at enrollment [85].

8. Hereditary autoinflammatory diseases

8.1. Diseases of Mendelian inheritance

A group of rare genetic disorders, which have a common phenotype of recurrent fevers, debilitating fatigue, myalgia, arthralgia, gastrointestinal symptoms and skin rashes, are treated with IL-1 blocking therapies. These include FMF, CAPS, TRAPS, HIDS, MKD and PAPA. Neutrophilia, elevated hepatic acute phase proteins and increased erythrocyte sedimentation rates are characteristic during the episodes. A common feature to nearly all hereditary autoinflammatory syndromes is the rapid and sustained arrest of both clinical and hematologic abnormalities to IL-1 blocking monotherapy, regardless whether the agent is anakinra, canakinumab or rilonacept (Tables 2, 5 and 6). However, in about 50% of the cases of FMF and CAPS, similar if not identical clinical and laboratory manifestations are present without the mutations. Elevated secretion of IL-1 β from blood monocytes in vitro can often be demonstrated.

8.2. Familial Mediterranean fever

Familial Mediterranean fever (FMF), known by episodes which last about three-four days and are characterized by fever, leukocytosis and severe serositis (mostly peritonitis, but pleuritis, pericarditis and synovitis occur). FMF is caused by mutations in the *MEFV* gene, encoding pyrin, a protein involved in the activation of caspase-1 and the processing and release of active IL-1 β [86]. Although colchicine is the mainstay of treatment, in a minority of patients colchicine is not sufficient to prevent the attacks. In several case reports, treatment with anakinra or canakinumab in colchicine-resistant patients is highly effective [87–94]. Not all patients with FMF have the classic mutation, despite classic signs and symptoms of the disease [95]. Whole exome sequencing revealed a novel missense sequence in FMF. The study concluded that heterozygous mutations at amino acid position 577 of pyrin can induce an autosomal dominant autoinflammatory syndrome [95].

8.3. Hyper-IgD syndrome

Hyper-IgD syndrome (HIDS) is an autosomal recessive autoinflammatory disorder caused by mutations in the mevalonate kinase gene; thus, HIDS is also known as mevalonate kinase deficiency (MKD). Several intracellular pathways of protein modification have linked mevalonate kinase deficiency to control of IL-1 production, as reviewed in [96], including activation of caspase-1 [97]. HIDS episodes last 4–6 days with fever, myalgia, skin rash,

aphthous ulcers and lymphadenopathy. Several case reports have demonstrated success of IL-1 blockade in reducing the frequency and severity of the attacks [96,98–103].

8.4. Cryopyrin associated periodic syndrome

Cryopyrin associated periodic syndrome (CAPS) is the term for three syndromes that were previously known under separate names: familial cold autoinflammatory syndrome, Muckle–Wells syndrome and neonatal onset multi inflammatory diseases. Each is linked to mutations in the NLRP3 inflammasome, which activates caspase-1 and results in increased release of IL-1 β [9,13–15,104–107]. The CAPS phenotype can vary from discrete inflammatory episodes of fever, myalgia and skin rash, lasting a few days, to almost continuous systemic inflammation with neurological involvement, including aseptic meningitis, raised intracranial pressure, deafness and growth retardation. Anakinra is highly efficacious in the treatment of CAPS (Table 2) and has been approved. Riloncept [108] as well as canakinumab [109–112] are approved for the treatment of this rare genetic disorder (Tables 5 and 6). A report of a 2-year follow-up of canakinumab treatment in 166 patients with CAPS revealed long-term efficacy with few side effects [113], even in previously severely affected patients with neurologic involvement. Sensorineural deafness is a common manifestation of CAPS as are other neurologic abnormalities but is reversible with IL-1 blockade [110,114,115].

8.5. TNF-receptor associated periodic syndrome

TNF-receptor associated periodic syndrome (TRAPS) is an autosomal dominant disease caused by mutations in the TNF-receptor type 1 [116]. Patients experience recurrent bouts of fever with local and systemic inflammation, initially thought to be due to a lack of circulating soluble TNF α receptors, which bind TNF α and prevent TNF α binding to cells [117]. However, treatment with IL-1 blockers is significantly more effective than with TNF inhibitors [118–120].

9. Chronic inflammatory diseases

A growing number of chronic inflammatory disorders without a known genetic basis respond to reducing IL-1 activity. For example, treating idiopathic recurrent pericarditis with immunosuppressive agents, anti-TNF α antibodies, non-steroidal anti-inflammatory agents, intravenous gamma globulin or high dose glucocorticoids often results partial remissions whereas anakinra (Table 3) provides complete remission in all cases reported [121–124]. Although most chronic inflammatory conditions without a known basis can be controlled with glucocorticoids, monotherapy with IL-1 blockade provides improved control without the metabolic and gastrointestinal side effects. In children, glucocorticoids retard growth and development and treating systemic onset juvenile idiopathic arthritis with anakinra or canakinumab allows for reduced glucocorticoid dosing and catchup growth [16,38,125,126] (Table 4).

9.1. Adult onset Still's disease

Adult onset Still's disease (AOSD) is a systemic inflammatory syndrome that is characterized by recurrent fevers, prominent neutrophilia, rash, systemic inflammation and arthritis with unusually high CRP and ferritin levels. Some patients develop a resistance to steroid therapy and anti-TNF α and methotrexate have been ineffective. In these patients monotherapy with anakinra is highly effective (Table 3) and has become the standard of therapy [127–131]. Canakinumab and riloncept are also effective in AOSD (Tables 5 and 6).

9.2. Systemic onset juvenile idiopathic arthritis

The juvenile form of Still's disease is called systemic onset juvenile idiopathic arthritis (SJIA) and is the severe form of juvenile idiopathic arthritis. As in the adult form, IL-1 contributes significantly to the inflammation in SJIA and several reports describe a remarkable efficacy with anakinra (see Table 3) in patients who are refractory to steroids, methotrexate and TNF blockers [16,126,132]. Neutralization of IL-1 β with canakinumab has been approved [38,133] (Table 5).

9.3. Schnitzler's syndrome

Schnitzler's syndrome is a debilitating systemic inflammatory disease characterized by repeated bouts of fever, chronic urticaria and a gammopathy. Patients with Schnitzler's syndrome can progress to hematopoietic malignancies. There is increased risk of developing Waldenström macroglobulinemia. Patients with Schnitzler syndrome are treated with anakinra, which results in rapid improvement, often within hours, and complete remission within days [134–138]. This effect has been observed in many cases, and the Schnitzler syndrome international registry, which collects data on Schnitzler's syndrome patients, reports nearly 100% efficacy with anakinra. Canakinumab [139] is also highly effective whereas depletion of B-cells with rituximab has failed to reduce the systemic symptoms.

9.4. Behçet's disease

The inflammation in Behçet's disease affects nearly all organs and tissues, as there is systemic vasculitis with oral, gastrointestinal and genital ulcers and a hypercoagulation state. Patients resistant to steroids respond to anakinra [140]. Uveitis and retinal vasculitis result in loss of sight and the use of glucocorticoids and immunosuppressive drugs are associated with significant adverse effects. Panuveitis was treated with a single dose of anti-IL-1 β (gevokizumab) and complete resolution of intraocular inflammation and return of vision was achieved in 4–21 days [141]. Treatment resulted in a rapid onset, marked and sustained reduction in intraocular inflammation in these refractory patients.

9.5. Dry eye disease

Anakinra was applied topically to patients with dry eye disease in a prospective, double-blinded, randomized trial involving 75 patients. Treatment was randomized to topical 2.5%, 5% anakinra or vehicle 3 times daily for 12 weeks. Subjects receiving 2.5% anakinra achieved a 46% reduction in their mean severity score ($P < 0.001$ compared with baseline) [142]. By week 12, treatment with 2.5% or 5% anakinra led to significant reductions in symptoms of 30% and 35%, respectively ($P = 0.02$ and $P = 0.01$, respectively, compared with vehicle).

9.6. Giant cell arteritis

Steroids are the treatment of choice in giant cell arteritis in order to save vision; however, alternate therapies for refractory cases are limited. IL-1 β expression is elevated in this disease as are other cytokines and chemokines. Three cases of refractory giant cell arteritis were successfully treated with anakinra [143]. Anakinra treatment was associated with reductions in inflammatory biomarkers as well as disappearance of arterial inflammation by PET/CT for two of the three patients treated [143].

9.7. Hidradenitis suppurativa

It is estimated that between 1 and 4% of the western world's population is affected by hidradenitis suppurativa. Inflammatory lesions derived from hair follicles in the groin, axilla and rectal areas and resulting in scarring characterize the disease. The disease is debilitating

both physiologically as well as socially due to the odorous nature of the inflammation. Although antibiotics are used, recurrences are common and presently, there is no treatment that reduces the fundamental nature of the follicular inflammation. Cytokine-mediated inflammation has been considered as immunosuppressive agents have been used. Blocking TNF α is effective in some patients but TNF α failures have been reported [144]. Elevated levels of TNF α as well as IL-1 β are released from 24 h cultures of skin from these patients; the elevated levels are not only in lesional skin biopsies but also in the unaffected peripheral skin of the lesions [145]. Blocking IL-1 with anakinra in hidradenitis suppurativa patients at the approved dose for rheumatoid arthritis (100 mg/day) is effective [146–149]. Canakinumab has also been reported as effective [150].

10. Other indications for treating IL-1-mediated inflammation

10.1. Mental impairment and hearing loss

CAPS patients exhibit various neurologic abnormalities such as aseptic lepto-meningitis and thus reflecting IL-1-mediated inflammation in the brain. In a study of CAPS patients, 92% had headache with features of migraine, 54% had sensorineural deafness and 46% had papilledema [110]. Treatment with either anakinra or canakinumab leads to complete resolution of symptoms [110,113,151]. Children with severe CAPS show manifestations of elevated intracranial pressure and are believed to be mentally slow or even retarded. However, both mental and hearing impairment are reversed upon treatment with anakinra [15,115,151–154] but also with specific neutralization of IL-1 β with canakinumab [109,111–113,155].

In autoimmune inner ear disease, there is either sudden onset or progressive loss in hearing. Patients are usually treated with glucocorticoids; however, those not responding to glucocorticoid therapy have elevated IL-1 β in the circulation and peripheral blood monocytes release more IL-1 β than monocytes from unaffected subjects [156]. Meniere Disease can also be characterized by progressive sensorineural hearing loss and is also associated with dysregulation of IL-1 β [156–158]. A randomized, placebo controlled trial of anakinra in Meniere disease has been initiated.

10.2. Amyloidosis

Amyloidosis is a destructive process for several organs due to the deposition of amyloid fibrils. IL-1 is an inducer of serum amyloid A (SAA), which is commonly elevated in several chronic inflammatory diseases, including atherosclerosis. Left untreated, IL-1-mediated diseases such as FMF and CAPS result in kidney failure due to amyloid deposits, which is fatal. However, treatment with anakinra, canakinumab or rilonacept markedly reduces SAA, kidney function improves and a fatal outcome can be avoided [89,91,159–162]. Amyloid deposits have also been observed in the insulin-producing islets where they may contribute to Type-2 diabetes [47]. Amyloid deposits in the brain are associated with Alzheimer disease and whether this pathogenic process can be arrested by IL-1-blocking therapies in this disease has been proposed [163].

10.3. Recurrent pericarditis

Although patients with AOSD and also other autoinflammatory diseases will have manifestation of pericarditis that is resolved with anakinra, canakinumab or rilonacept, idiopathic recurrent pericarditis is also responsive to anakinra [121–123,164–167].

10.4. Multiple sclerosis and neuromyelitis optica

Patients being treated with TNF α blockers may have clinical and magnetic resonance imaging (MRI) evidence of brain demyelination or exacerbations of existing multiple

sclerosis (MS) [168]. The FDA requires labels for all TNF α blockers state the risk. Is anakinra treatment also a risk for MS or demyelination? In a cohort of 104,000 patients with rheumatoid arthritis (87% females), those patients without a history of MS or optic neuritis who were treated with anti-TNF α agents revealed an adjusted rate ratio of 1.31 whereas those treated with anakinra had a rate of 0.80 [169]. Levels above 1.0 indicate more disease whereas levels below 1.0 indicate less disease. The lower disease level of anakinra is consistent with preclinical reports of a protective effect of IL-1 blockade in mice exposed to allergic autoimmune encephalitis, the model for MS. Also, interferon- β (IFN β), widely used to treat MS, induces IL-1Ra in microglia and IL-1Ra levels are increased in the serum of progressive MS patients during IFN β therapy. Thus, there is a clear rationale for a trial of anakinra in MS, optic neuritis and neuromyelitis optica, which is a severe form of optic neuritis.

10.5. Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive loss of motor neurons resulting in death within a few years following diagnosis. The pathogenesis of ALS is associated with mutations in superoxide dismutase-1 (SOD1), in which a misfolding of this protein results in increased neuroinflammation. In a mouse model of mutant SOD1 as well as in ALS patients, IL-1 β levels are elevated [170]. Deficiency in caspase-1 or IL-1 β or treatment with anakinra extended the lifespan of the SOD1 transgenic mice and attenuated inflammatory pathology [170]. There is a case report of a patient being treated with anakinra for acquired cold urticaria in which improvement in the early manifestations of ALS was observed [171]. Therefore, there is a rationale for treating ALS with IL-1 β blockade [172]. A trial is underway using anakinra to treat ALS patients early in the course of their disease.

10.6. Inflammation in the demise of hemodialysis

A role for IL-1 in the systemic and local inflammation of hemodialysis has been a topic of many studies [173]. Patients with endstage renal disease on maintenance hemodialysis have increased risk of all cause mortality as serum albumin levels fall. In a randomized, placebo controlled trial of 4 weeks of anakinra in these patients, there was a 23% increase in mean albumin compared with 6% in the placebo arm [174]. In addition, markers of systemic inflammation such as CRP and IL-6 fell significantly [174]. Extending the duration of IL-1 blockade would assess whether treatment improves survival.

11. Anti-IL-1 α

The monoclonal antibody against IL-1 α is being tested in Type 2 diabetes, cancer, cancer cachexia, leukemia, psoriasis, vascular disease and scarring acne vulgaris. Indeed, inflammation resulting from ischemic damage starts with the release of the IL-1 α precursor from dying cells. The IL-1 α is active (Fig. 2) but as the inflammation progresses, IL-1 β becomes the dominant cytokine the process becomes an IL-1 β -mediated process. Due to its specificity and long half-life, neutralization of IL-1 β is emerging an optimal agent for some diseases such as in the CANTOS trial; nevertheless, there are specific disease conditions in which anakinra, particularly given intravenously, provides an optimal therapy for some diseases. In fact, intravenous anakinra is the preferred IL-1 blocking therapy in acute conditions such as MAS due to its ability to prevent either IL-1 α or IL-1 β activity, its long history of safety even at doses 100–1000-fold higher than the subcutaneous dose, and upon stoppage, blood levels fall within hours, providing another aspect for safety.

12. Smoldering/indolent myeloma

In the microenvironment of the bone marrow, IL-1 β produced by myeloma precursor plasma cells stimulates the stromal cells to release large amounts of IL-6, which in turn promotes

the survival and expansion of the pre-myeloma cells [175]. It was reasoned that in the indolent stages of multiple myeloma, blocking IL-1 β would reduce IL-6 activity [176]. Patients with smoldering or indolent myeloma at high risk for progression to multiple myeloma were selected with the clinical objective of slowing or preventing progression to active disease. During 6 months of treatment with anakinra, there were decreases in CRP in most but not all patients, which paralleled a decrease in myeloma cell proliferation. After 6 months of anakinra, a low dose of dexamethasone was added. Of the 47 patients that received anakinra with dexamethasone, progression-free disease was over three years and in 8 patients over 4 years [176]. Compared to historical experience, the findings indicate a significant failure to progress to active disease. Given the increasing incidence of multiple myeloma in the aging population, an option of anti-IL-1 β as an early intervention treatment in the indolent stages of multiple myeloma might have a significant impact on this fatal cancer.

13. Safety issues with IL-1 blockade

13.1. IL-1 and host defense against infection

Since its introduction in 2002, anakinra has had a remarkable record of safety [61,177]. It is estimated that over 150,000 patients have received anakinra, some treated daily for over 10 years. Anakinra has been administered to patients with active infections [178,179]. Following the introduction of anti-TNF α blocking therapies, a wide-spectrum of opportunistic infections were reported, similar to those observed in immunosuppressed persons. Host defense against opportunistic organisms as well as routine bacterial infections have since become a major concern for all anti-cytokine agents because of the indolent and dangerous nature of these infections. Reactivation of latent *Mycobacterium tuberculosis* in patients receiving anti-TNF α therapies can be 25-times higher than in untreated persons [180] and is often the disseminated form, similar to that observed in HIV-1 infected patients. *M. tuberculosis* also occurs in patients treated with TNF β blockers without evidence of prior exposure to the organism. In contrast, opportunistic infections in patients treated with anakinra are rare [181], including populations at high risk for reactivation of *M. tuberculosis* infections [182]. There is a single case report of a 77 year old man with severe rheumatoid arthritis and a history of pulmonary tuberculosis who developed reactivation 23 months after starting anakinra [183]. Despite tuberculin testing each patient before beginning any anti-cytokine for previous exposure to *M. tuberculosis*, reactivation continues to occur in patients and can be as high as 9.3% with the notable exception of anakinra [184].

During controlled trials of anakinra, canakinumab and rilonacept, there were more viral-type upper airway infections compared to placebo-treated patients but these type infections are also reported for all biologics. Although these upper airway infections are not life-threatening, bacterial infection with organisms such as *Streptococcus pneumoniae* and *Staphylococcus aureus* are of concern in any patient receiving a biologic. However, in hidradenitis suppurativa with skin flora of *S. aureus*-infected apocrine glands, anakinra treatment resolves the inflammatory nature of the disease without increasing the infection [146,185–187]. Also in patients with chronic granulomatous disease, an inherited condition with multiple bouts of infections with Gram-positive and Gram-negative bacteria as well as fungi, treatment with anakinra reduces the severity of inflammatory bowel disease and granulomas associated with the disease without increased infection [178]. Although use of anti-IL-1 β monoclonal antibodies and the soluble IL-1 receptor rilonacept are relatively recent compared to the experience with anakinra, there has been no unexpected increase in infections.

13.2. Effects of IL-1 on hematopoiesis

One of the more salient properties of IL-1 is its ability to increase circulating neutrophil numbers (reviewed in [188]). Only 3 ng/kg of IL-1 β injected into humans results in a neutrophilia [189]. To shorten the nadir in neutrophils following chemotherapy for bone marrow transplantation, low doses of either IL-1 α or IL-1 β were administered as hematopoietic factors; increased neutrophilic responses were consistently reported (reviewed in [188]). Neutrophilia is perhaps the most characteristic findings in many IL-1-mediated inflammatory diseases, particularly in autoinflammatory diseases. Thus, a response to IL-1 blockade is usually heralded by a mild to modest reduction in circulating neutrophils, rarely falls below the normal range, is an indication of efficacy, not bone-marrow suppression. In healthy subjects, intravenous infusions of anakinra at 10 mg/kg did not affect peripheral neutrophil counts [190]. Sustained neutropenia is not observed and neutrophils rapidly rise upon cessation of treatment [85].

Acknowledgments

The author thanks A. Abbate, M. Donath, T. Mandrup-Poulsen, M. G. Netea, B. Pilstrom, and Anna Simon for their assistance with this review. This work is supported by NIH Grants AI-15614, AR-45584 (to CAD).

Abbreviations

FMF	familial Mediterranean fever
FCAS	familial cold autoinflammatory syndrome
NOMID	neonatal onset multi-inflammatory diseases
CAPS	cryopyrin autoinflammatory periodic syndromes
TRAPS	TNF receptor associated periodic syndrome
HIDS	hyper IgD syndrome
PAPA	pyogenic arthritis, pyoderma gangrenosum, and acne
DIRA	deficiency of IL-1Ra
SAPHO	synovitis, acne, pustulosis, hyperostosis and osteitis
PASH	pyoderma-gangrenosum, acne, and suppurativa hidradenitis
PFAPA	periodic fever, aphthous stomatitis, pharyngitis, and adenitis
SJIA	systemic-onset juvenile idiopathic arthritis
NLRP3	nucleotide-binding domain and leucine-rich repeat pyrin containing 3
NLRP12	nucleotide-binding domain and leucine-rich repeat pyrin containing 12
AOSD	adult onset Still's disease
CRP	C-reactive protein

References

1. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. *N Engl J Med.* 2009; 360:2438–44. [PubMed: 19494219]
2. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. *N Engl J Med.* 2009; 360:2426–37. [PubMed: 19494218]

3. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. *J Exp Med.* 2009; 206:1029–36. [PubMed: 19364880]
4. Berda-Haddad Y, Robert S, Salers P, Zekraoui L, Farnarier C, Dinarello CA, et al. Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha. *Proc Natl Acad Sci U S A.* 2011; 108:20684–9. [PubMed: 22143786]
5. Beyer C, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatic diseases. *Nat Rev Rheumatol.* 2011; 6:21–9. [PubMed: 19949432]
6. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, et al. IL-1 α and IL-1 β recruit different myeloid cells and promote different stages of sterile inflammation. *J Immunol.* 2011; 187:4835–43. [PubMed: 21930960]
7. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. *Proc Natl Acad Sci U S A.* 2010; 107:2574–9. [PubMed: 20133797]
8. Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, Cannon JG, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. *J Immunol.* 1987; 139:1902–10. [PubMed: 3497982]
9. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta processing inflammasome with increased activity in Muckle–Wells auto-inflammatory disorder. *Immunity.* 2004; 20:319–25. [PubMed: 15030775]
10. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. *Annu Rev Immunol.* 2009; 27:229–65. [PubMed: 19302040]
11. Hoffman HM, Brydges SD. Genetic and molecular basis of inflammasome-mediated disease. *J Biol Chem.* 2011; 286:10889–96. [PubMed: 21296874]
12. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. *Annu Rev Immunol.* 2009; 27:621–68. [PubMed: 19302049]
13. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum.* 2008; 58:1505–15. [PubMed: 18438814]
14. Gattorno M, Tassi S, Carta S, Delfino L, Ferlito F, Pelagatti MA, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. *Arthritis Rheum.* 2007; 56:3138–48. [PubMed: 17763411]
15. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. *N Engl J Med.* 2006; 355:581–92. [PubMed: 16899778]
16. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. *J Exp Med.* 2005; 201:1479–86. [PubMed: 15851489]
17. Colina M, Pizzirani C, Khodeir M, Falzoni S, Bruschi M, Trotta F, et al. Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. *Rheumatology (Oxford).* 2010; 49:1416–8. [PubMed: 20299381]
18. Dinarello CA. Anti-inflammatory agents: present and future. *Cell.* 2010; 140:935–50. [PubMed: 20303881]
19. Dinarello CA. How interleukin-1beta induces gouty arthritis. *Arthritis Rheum.* 2010; 62:3140–4. [PubMed: 20662058]
20. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol.* 2011; 11:98–107. [PubMed: 21233852]
21. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. *Circulation.* 2008; 117:2670–83. [PubMed: 18474815]
22. Abraham E, Allbee J. Effects of therapy with interleukin-1 receptor antagonist on pulmonary cytokine expression following hemorrhage and resuscitation. *Lymphokine Cytokine Res.* 1994; 13:343–7. [PubMed: 7703308]

23. Calkins CM, Bensard DD, Shames BD, Pulido EJ, Abraham E, Fernandez N, et al. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. *J Endotoxin Res.* 2002; 8:59–67. [PubMed: 11981446]
24. Rusai K, Huang H, Sayed N, Strobl M, Roos M, Schmaderer C, et al. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. *Transpl Int.* 2008; 21:572–80. [PubMed: 18363573]
25. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ. Role of IL-1alpha and IL-1beta in ischemic brain damage. *J Neurosci.* 2001; 21:5528–34. [PubMed: 11466424]
26. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. *J Neurol Neurosurg Psychiatry.* 2005; 76:1366–72. [PubMed: 16170078]
27. Abbate A, Van Tassell BW, Biondi-Zoccai GG. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. *Bio-Drugs.* 2012; 26:217–33.
28. Abbate A, Van Tassell BW, Seropian IM, Toldo S, Robati R, Varma A, et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodeling following acute myocardial infarction in the mouse. *Eur J Heart Fail.* 2010; 12:319–22. [PubMed: 20335350]
29. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. *Am J Cardiol.* 2013; 111:1394–400. [PubMed: 23453459]
30. Van Tassell BW, Arena R, Toldo S, Mezzaroma E, Azam T, Seropian IM, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. *PLOS One.* 2012; 7:e33438. [PubMed: 22438931]
31. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. *Circulation.* 2008; 117:2662–9. [PubMed: 18474811]
32. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor- α and interleukin-1 β synergistically depress human myocardial function. *Crit Care Med.* 1999; 27:1309–18. [PubMed: 10446825]
33. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. *Proc Natl Acad Sci U S A.* 2001; 98:2871–6. [PubMed: 11226333]
34. Van Tassell BW, Arena R, Canad J, Biondi-Zoccai GG, Oddi C, Abouzaki NA, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure with preserved ejection fraction. *Am Heart J.* 2013 in press.
35. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. *Nat Rev Endocrinol.* 2010; 6:158–66. [PubMed: 20173777]
36. Dayer-Metroz MD, Duhamel D, Rufer N, Izui S, Carmichaels D, Wollheim CB, et al. IL-1ra delays the spontaneous autoimmune diabetes in the BB rat. *Eur J Clin Invest.* 1992; 22:A50. abs.
37. Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. *Pediatr Diabetes.* 2011; 12:656–67. [PubMed: 21518168]
38. Ruperto N, Quartier P, Wulfraat N, Woo P, Loy A, Mouy R, et al. Evaluation of safety and preliminary efficacy of canakinumab in children with systemic onset juvenile idiopathic arthritis. *Arthr Rheumat.* 2009; 60(Suppl 10):2055. [PubMed: 19565498]
39. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. *Arthritis Rheum.* 2012; 64:2375–86. [PubMed: 22294344]
40. Bach JF, Chatenoud L. A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. *Semin Immunol.* 2012; 23:174–81. [PubMed: 21846589]

41. Bach JF, Feutren G, Noel LH, Hannedouche T, Landais P, Timsit J, et al. Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels. *Transplant Proc.* 1990; 22:1296–8. [PubMed: 2349690]
42. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. *N Engl J Med.* 2002; 346:1692–8. [PubMed: 12037148]
43. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. *N Engl J Med.* 2009; 361:2143–52. [PubMed: 19940299]
44. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab.* 2011; 96:2119–26. [PubMed: 21508140]
45. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. *Lancet.* 2013; 381:1905–15. [PubMed: 23562090]
46. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinass GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. *J Clin Invest.* 2002; 110:851–60. [PubMed: 12235117]
47. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. *Nat Immunol.* 2010; 11:897–904. [PubMed: 20835230]
48. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N Engl J Med.* 2007; 356:1517–26. [PubMed: 17429083]
49. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. *Diabetes Care.* 2009; 32:1663–8. [PubMed: 19542207]
50. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. *Diabetes Care.* 2012; 35:1654–62. [PubMed: 22699287]
51. Rissanen A, Howard C, Botha J, Thuren T. IL-1beta antibody (canakinumab) improves insulin secretion rates in subjects with impaired glucose tolerance and type 2 diabetes. *Diabetes.* 2011; 60(Suppl 1A)
52. Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. *Diabetes Care.* 2013; 36:2239–46. [PubMed: 23514733]
53. Cavelti-Weder C, Furrer R, Keller C, Babians-Brunner A, Solinger AM, Gast H, et al. Inhibition of IL-1beta improves fatigue in type 2 diabetes. *Diabetes Care.* 2011; 34:e158. [PubMed: 21949230]
54. Norheim KB, Harboe E, Goransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome—a double blind, randomised clinical trial. *PLOS One.* 2012; 7:e30123. [PubMed: 22253903]
55. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. *Cell Metab.* 2011; 12:593–605. [PubMed: 21109192]
56. Kamari Y, Werman-Venkert R, Shaish A, Werman A, Harari A, Gonen A, et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. *Atherosclerosis.* 2007; 195:31–8. [PubMed: 17173923]
57. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature.* 2010; 464:1357–61. [PubMed: 20428172]
58. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol.* 2009; 54:2129–38. [PubMed: 19942084]

59. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). *Am Heart J.* 2011; 162:597–605. [PubMed: 21982649]
60. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. *Circulation.* 2012; 126:2739–48. [PubMed: 23129601]
61. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. *J Rheumatol.* 2009; 36:1118–25. [PubMed: 19447938]
62. Botsios C, Sfriso P, Furlan A, Ostuni P, Biscaro M, Fiocco U, et al. Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice, Outcome in 60 patients with severe rheumatoid arthritis. *Reumatismo.* 2007; 59:32–7. [PubMed: 17435840]
63. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis, extension of a 24-week randomized, placebo-controlled trial. *J Rheumatol.* 2004; 31:1103–11. [PubMed: 15170922]
64. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. *Arthritis Rheum.* 2000; 43:1001–9. [PubMed: 10817552]
65. Genant HK, Bresnihan B, Ng E, Robbins S, Newmark RD, McCabe D. Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis. *Ann Rheum Dis.* 2001; 40(Suppl 1):169. abs.
66. Miller DM, Ng E, Schiff MH, Cohen SB, Bresnihan B. Durability and rapidity of response for rheumatoid arthritis patients receiving therapy with anakinra. *Ann Rheum Dis.* 2001; 60(Suppl 1): 171. abs.
67. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. *Proc Natl Acad Sci U S A.* 2011; 108:3731–6. [PubMed: 21245297]
68. Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, et al. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. *BMC Musculoskelet Disord.* 2011; 12:153. [PubMed: 21736751]
69. Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. *Arthritis Rheum.* 2009; 61:1268–70. [PubMed: 19714614]
70. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. *Ann Rheum Dis.* 2007; 66:1683–4. [PubMed: 17998217]
71. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. *Arthritis Rheum.* 2008; 58:631–3. [PubMed: 18240249]
72. Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout. *J Clin Rheumatol.* 2009; 15:366. [PubMed: 20009976]
73. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. *Arthritis Rheum.* 2010; 62:3064–76. [PubMed: 20533546]
74. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. *Arthritis Res Ther.* 2007; 9:R28. [PubMed: 17352828]
75. Terkeltaub R, Sundry JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. *Ann Rheum Dis.* 2009; 68:1613–7. [PubMed: 19635719]
76. Terkeltaub R. Update on gout: new therapeutic strategies and options. *Nat Rev Rheumatol.* 2010; 6:30–8. [PubMed: 20046204]

77. Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. *Joint Bone Spine*. 2009; 76:424–6. [PubMed: 19289295]
78. Schlesinger N, De Meulemeester M, Pikhak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. *Arthritis Res Ther*. 2012; 13:R53. [PubMed: 21439048]
79. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovinsky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. *Ann Rheum Dis*. 2011; 70:1264–71. [PubMed: 21540198]
80. Joosten LA, Netea MG, Mylona E, Koenders MI, Malireddi RK, Oosting M, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. *Arthritis Rheum*. 2010; 62:3237–48. [PubMed: 20662061]
81. Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H, et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. *Arthritis Rheum*. 2009; 60:3651–62. [PubMed: 19950280]
82. Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. *Ann Rheum Dis*. 2009; 68:1078–9. [PubMed: 19435727]
83. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. *J Rheumatol*. 2005; 32:1317–23. [PubMed: 15996071]
84. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum*. 2009; 61:344–52. [PubMed: 19248129]
85. Cohen SB, Proudman S, Kivitz AJ, Burch FX, Donohue JP, Burstein D, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoarthritis of the knee. *Arthritis Res Ther*. 2011; 13:R125. [PubMed: 21801403]
86. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. *Br J Haematol*. 2009; 146:467–78. [PubMed: 19466978]
87. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30. 2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. *Proc Natl Acad Sci U S A*. 2006; 103:9982–7. [PubMed: 16785446]
88. Alenazi A, Al Sonbul A, Al Jumaah S, Al Mehadib A, Al-Mayouf SM. A retrospective review of autoinflammatory diseases in Saudi children at a rheumatology clinic. *Ann Saudi Med*. 2012; 32:43–8. [PubMed: 22156639]
89. Stankovic Stojanovic K, Delmas Y, Urena Torres P, Peltier J, Pelle G, Jeru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. *Nephrol Dial Transplant*. 2012; 27:1898–901. [PubMed: 21931121]
90. Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. *Clin Rheumatol*. 2010; 29:209–10. [PubMed: 19774408]
91. Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. *Nephrol Dial Transplant*. 2009; 24:676–8. [PubMed: 19033248]
92. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. *Semin Arthritis Rheum*. 2011; 41:265–71. [PubMed: 21277619]
93. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. *Eur J Pediatr*. 2008; 167:695–6. [PubMed: 17588171]

94. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. *Ann Rheum Dis.* 2010; 70:1347–8. [PubMed: 21345814]
95. Stoffels M, Szperl A, Simon A, Netea MG, Plantinga TS, van Deuren M, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. *Ann Rheum Dis.* 2013
96. Stoffels M, Simon A. Hyper-IgD syndrome or mevalonate kinase deficiency. *Curr Opin Rheumatol.* 2011; 23:419–23. [PubMed: 21760510]
97. Gosavi S, Chavez LL, Jennings PA, Onuchic JN. Topological frustration and the folding of interleukin-1 beta. *J Mol Biol.* 2006; 357:986–96. [PubMed: 16469330]
98. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. *Ann Rheum Dis.* 2011; 70:2155–8. [PubMed: 21859689]
99. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. *Neth J Med.* 2005; 63:260–4. [PubMed: 16093577]
100. Cailliez M, Garaix F, Rousset-Rouviere C, Bruno D, Kone-Paut I, Sarles J, et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. *J Inherit Metab Dis.* 2006; 29:763. [PubMed: 17103011]
101. Korppi M, Van Gijn ME, Antila K. Hyperimmunoglobulinemia D and periodic fever syndrome in children, review on therapy with biological drugs and case report. *Acta Paediatr.* 2011; 100:21–5. [PubMed: 20712835]
102. Shendi HM, Walsh D, Edgar JD. Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. *Rheumatol Int.* 2012; 32:249–51. [PubMed: 20020131]
103. van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. *Medicine (Baltimore).* 2008; 87:301–10. [PubMed: 19011501]
104. Rosengren S, Mueller JL, Anderson JP, Niehaus BL, Misaghi A, Anderson S, et al. Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia. *J Allergy Clin Immunol.* 2007; 119:991–6. [PubMed: 17320940]
105. Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JC, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. *J Immunol.* 2005; 175:2630–4. [PubMed: 16081838]
106. Tassi S, Carta S, Delfino L, Caorsi R, Martini A, Gattorno M, et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. *Proc Natl Acad Sci U S A.* 2010; 107:9789–94. [PubMed: 20445104]
107. Hedrich CM, Bruck N, Paul D, Hahn G, Gahr M, Rosen-Wolff A. “Mutation negative” familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies. *Rheumatol Int.* 2012; 32:2629–36. [PubMed: 21833523]
108. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. *Arthritis Rheum.* 2008; 58:2443–52. [PubMed: 18668535]
109. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. *N Engl J Med.* 2009; 360:2416–25. [PubMed: 19494217]
110. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. *Neurology.* 2010; 74:1267–70. [PubMed: 20404307]
111. Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind

- placebo-controlled randomized withdrawal study. *Arthritis Res Ther.* 2011; 13:R202. [PubMed: 22152723]
112. Kummerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). *Arthritis Res Ther.* 2011; 13:R34. [PubMed: 21356079]
 113. Kummerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. *Ann Rheum Dis.* 2011; 70:2095–102. [PubMed: 21859692]
 114. Ahmadi N, Brewer CC, Zalewski C, King KA, Butman JA, Plass N, et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. *Otolaryngol Head Neck Surg.* 2011; 145:295–302. [PubMed: 21493283]
 115. Klein AK, Horneff G. Improvement of sensorineural hearing loss in a patient with Muckle–Wells syndrome treated with anakinra. *Klin Padiatr.* 2011; 222:266–8. [PubMed: 20135584]
 116. McDermott MF, Aksentjevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell.* 1999; 97:133–44. [PubMed: 10199409]
 117. Galon J, Aksentjevich I, McDermott MF, O’Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. *Curr Opin Immunol.* 2000; 12:479–86. [PubMed: 10899034]
 118. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. *Arthritis Rheum.* 2008; 58:1516–20. [PubMed: 18438813]
 119. Simon A, Bodar EJ, van der Hilst JCH, Van der Meer JW, Fiselier TJW, Cuppen MPJM, et al. Beneficial response to interleukin-1 receptor antagonist in TRAPS. *Am J Med.* 2004; 117:208–10. [PubMed: 15300976]
 120. Sacre K, Brihaye B, Lidove O, Papo T, Pocard MA, Cuisset L, et al. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. *J Rheumatol.* 2008; 35:357–8. [PubMed: 18260167]
 121. Cantarini L, Lucherini OM, Cimaz R, Galeazzi M. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. *Clin Exp Rheumatol.* 2010; 28:802. [PubMed: 21029567]
 122. Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? *Arthritis Rheum.* 2009; 60:264–8. [PubMed: 19116906]
 123. Scott IC, Vijay Hajela V, Hawkins PN, Lachmann HJ. A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. *J Cardiol Cases.* 2011; 4:e93–7.
 124. Kummerle-Deschner JB, Lohse P, Koetter I, Dannecker GE, Reess F, Ummenhofer K, et al. NLRP3 E311K mutation in a large family with Muckle–Wells syndrome—description of a heterogeneous phenotype and response to treatment. *Arthritis Res Ther.* 2011; 13:R196. [PubMed: 22146561]
 125. Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). *Rheumatology (Oxford).* 2008; 47:555–6. [PubMed: 18321945]
 126. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). *Ann Rheum Dis.* 2011; 70:747–54. [PubMed: 21173013]
 127. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. *Ann Rheum Dis.* 2010; 69:466–7. [PubMed: 20107032]

128. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. *Ann Rheum Dis.* 2008; 67:302–8. [PubMed: 17947302]
129. Kotter I, Wacker A, Koch S, Henes J, Richter C, Engel A, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. *Semin Arthritis Rheum.* 2007; 37:189–97. [PubMed: 17583775]
130. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. *Ann Rheum Dis.* 2007; 66:842–3. [PubMed: 17513574]
131. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. *Arthritis Rheum.* 2005; 52:1794–803. [PubMed: 15934079]
132. Swart JF, Barug D, Mohlmann M, Wulffraat NM. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. *Expert Opin Biol Ther.* 2010; 10:1743–52. [PubMed: 20979564]
133. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. *Arthritis Rheum.* 2012; 64:557–67. [PubMed: 21953497]
134. De Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, Van der Meer JW. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. *Ann Rheum Dis.* 2006; 65:542–4. [PubMed: 16096327]
135. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. *Arthritis Rheum.* 2005; 52:2226–7. [PubMed: 15986356]
136. de Koning HD, van der Meer JW, Simon A. Comment on: Schnitzler's syndrome—exacerbation after anti-TNF treatment. *Rheumatology (Oxford).* 2007; 46:1741. author reply 1741. [PubMed: 17956920]
137. Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. *J Allergy Clin Immunol.* 2008; 121:260–2. [PubMed: 17936890]
138. Szturz P, Adam Z, Sediva A, Fojtik Z, Corbova D, Neubauer J, et al. Schnitzler syndrome: diagnostics and treatment. *Klin Onkol.* 2011; 24:271–7. [PubMed: 21905617]
139. de Koning HD, Schalkwijk J, van der Meer JW, Simon A. Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. *J Allergy Clin Immunol.* 2011; 128:1352–4. [PubMed: 21704363]
140. Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. *Joint Bone Spine.* 2008; 75:366–7. [PubMed: 18068393]
141. Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. *Ann Rheum Dis.* 2012; 71:563–6. [PubMed: 22084392]
142. Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. *JAMA Ophthalmol.* 2013; 131:715–23. [PubMed: 23599118]
143. Ly KH, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais AL. Interleukin-1 blockade in refractory giant cell arteritis. *Joint Bone Spine.* 2013
144. van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. *Dermatology.* 2013; 226:97–100. [PubMed: 23713053]
145. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis

- suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. *Br J Dermatol.* 2011; 164:1292–8. [PubMed: 21332464]
146. Zarchi K, Dufour DN, Jemec GB. Successful Treatment of Severe Hidradenitis Suppurativa With Anakinra. *JAMA Dermatol.* 2013; 149:1192–4. [PubMed: 23966107]
147. Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. *Curr Clin Pharmacol.* 2012; 7:271–5. [PubMed: 22794157]
148. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. *J Am Acad Dermatol.* 2012; 66:409–15. [PubMed: 21745697]
149. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. *Arch Dermatol.* 2010; 146:1265–70. [PubMed: 21079064]
150. Jaeger T, Andres C, Grosber M, Zirbs M, Hein R, Ring J, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa—rapid response to canakinumab (anti-IL-1beta). *Eur J Dermatol.* 2013
151. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. *Curr Rheumatol Rep.* 2011; 13:123–31. [PubMed: 21538043]
152. Lepore L, Paloni G, Caorsi R, Alessio M, Rigante D, Ruperto N, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. *J Pediatr.* 2011; 157:310–5. e311. [PubMed: 20472245]
153. Miyamae T, Inaba Y, Nishimura G, Kikuchi M, Kishi T, Hara R, et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. *Pediatr Rheumatol Online J.* 2011; 8:9. [PubMed: 20230645]
154. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis Rheum.* 2011; 62:258–67. [PubMed: 20039428]
155. Mueller SM, Itin P, Haeusermann P. Muckle–Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory? *Dermatology.* 2011; 223:113–8. [PubMed: 21967869]
156. Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. IL-1beta is over-expressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. *J Immunol.* 2011; 186:1870–9. [PubMed: 21199898]
157. Furuta T, Teranishi M, Uchida Y, Nishio N, Kato K, Otake H, et al. Association of interleukin-1 gene polymorphisms with sudden sensorineural hearing loss and Meniere's disease. *Int J Immunopharmacol.* 2011; 38:249–54.
158. Vambutas A, DeVoti J, Goldofsky E, Gordon M, Lesser M, Bonagura V. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. *PLoS One.* 2009; 4:e5293. [PubMed: 19401759]
159. Ait-Abdesselam T, Lequerre T, Legallicier B, Francois A, Le Loet X, Vittecoq O. Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. *Joint Bone Spine.* 2011; 77:616–7. [PubMed: 20609610]
160. Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. *Clin Rheumatol.* 2010; 29:209–10. [PubMed: 19774408]
161. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. *Arthritis Rheum.* 2011; 63:840–9. [PubMed: 21360513]
162. Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. *Am J Kidney Dis.* 2007; 49:477–81. [PubMed: 17336710]
163. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. *Neurology.* 2007; 68:1902–8. [PubMed: 17536046]

164. Camacho-Lovillo M, Mendez-Santos A. Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra). *Pediatric Cardiol.* 2013; 34:1293–4.
165. Scardapane A, Brucato A, Chiarelli F, Breda L. Efficacy of an interleukin-1beta receptor antagonist (anakinra) in idiopathic recurrent pericarditis. *Pediatric cardiology.* 2012 in press.
166. Vassilopoulos D, Lazaros G, Tsioufis C, Vasileiou P, Stefanadis C, Pectasides D. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). *Int J Cardiol.* 2012; 160:66–8. [PubMed: 22704870]
167. Seferovic PM, Ristic AD, Maksimovic R, Simeunovic DS, Milinkovic I, Seferovic Mitrovic JP, et al. Pericardial syndromes: an update after the ESC guidelines 2004. *Heart Fail Rev.* 2013; 18:255–66. [PubMed: 22855353]
168. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. *Infect Immun.* 2001; 69:1847–55. [PubMed: 11179363]
169. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. *Ann Rheum Dis.* 2010; 69:1691–3. [PubMed: 19628820]
170. Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. *Proc Natl Acad Sci U S A.* 2010; 107:13046–50. [PubMed: 20616033]
171. Bodar EJ, Simon A, de Visser M, van der Meer JW. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). *Neth J Med.* 2009; 67:302–5. [PubMed: 19841487]
172. van der Meer JW, Simon A. Blocking IL-1beta to slow down progression of ALS? *Proc Natl Acad Sci U S A.* 2010; 107:12741–2. [PubMed: 20624959]
173. Dinarello CA, Koch KM, Shaldon S. Interleukin-1 and its relevance in patients treated with hemodialysis. *Kidney Int.* 1988; 33:S21–6.
174. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA. IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. *J Am Soc Nephrol.* 2011; 22:437–42. [PubMed: 21310819]
175. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. *Hematol Oncol Clin North Am.* 1999; 13:1117–25. [PubMed: 10626139]
176. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. *Mayo Clin Proc.* 2009; 84:114–22. [PubMed: 19181644]
177. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2006; 65:1006–12. [PubMed: 16396977]
178. van de Veerdonk FL, Netea MG, Dinarello CA, van der Meer JW. Anakinra for the inflammatory complications of chronic granulomatous disease. *Neth J Med.* 2011; 69:95. [PubMed: 21411850]
179. Hennig S, Bayegan K, Uffmann M, Thalhammer F, Winkler S. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review. *Rheumatol Int.* 2012; 32:1801–4. [PubMed: 20352226]
180. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. *J Eur Respir.* 2011; 36:1185–206.
181. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. *Arthritis Rheum.* 2003; 48:927–34. [PubMed: 12687534]
182. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum.* 1998; 41:2196–204. [PubMed: 9870876]

183. Settas LD, Tsimirikas G, Vosvotekas G, Triantafyllidou E, Nicolaidis P. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). *J Clin Rheumatol*. 2007; 13:219–20. [PubMed: 17762459]
184. Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON((R))-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. *Br J Dermatol*. 2011; 164:553–9. [PubMed: 21083541]
185. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. *J Am Acad Dermatol*. 2012; 66:409–15. [PubMed: 21745697]
186. Netea MG, van de Veerdonk FL, Joosten LAB, Giamarellos-Bourboulis EJ, Simon A, Kullberg BJ, et al. Overproduction of interleukin-17 in a family with hidradenitis suppurativa: response to anakinra therapy. *J Invest Dermatol*. 2013 in press.
187. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. *Arch Dermatol*. 2011; 146:1265–70. [PubMed: 21079064]
188. Dinarello CA. Biological basis for interleukin-1 in disease. *Blood*. 1996; 87:2095–147. [PubMed: 8630372]
189. Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, Thomsen LL, et al. IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. *J Immunol*. 1996; 156:389–94. [PubMed: 8598489]
190. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. *Cytokine*. 1992; 4:353–60. [PubMed: 1420996]
191. Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. *Rheumatology (Oxford)*. 2002; 41:972–80. [PubMed: 12209029]
192. Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2003; 42(Suppl 2):ii22–8. [PubMed: 12817092]
193. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Sao Paulo Med J*. 2010; 128:309–10. [PubMed: 21181074]
194. Bao J, Yue T, Liu W, Zhang Q, Zhou L, Xu HJ, et al. Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. *Clin Rheumatol*. 2011; 30:697–701. [PubMed: 21221689]
195. Bresnihan B, Newmark RD, Robbins S, McCabe DP, Genant HK. Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis. *Arthritis Rheum*. 2000; 43(Suppl 9):S289.
196. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. *Rheumatology (Oxford)*. 2001; 40:62–9. [PubMed: 11157143]
197. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. *Pharmacotherapy*. 2011; 31:39–51. [PubMed: 21182357]
198. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. *J Rheumatol*. 2011; 38:821–7. [PubMed: 21362762]
199. Turkstra E, Ng SK, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. *Curr Med Res Opin*. 2011; 27:1885–97. [PubMed: 21848493]
200. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. *Rheumatology (Oxford)*. 2007; 46:1140–7. [PubMed: 17478472]
201. Cohen SB, Strand V, Aguilar D, Ofman JJ. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. *Rheumatology (Oxford)*. 2004; 43:704–11. [PubMed: 14997006]

202. Cohen SB. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. *Rheum Dis Clin North Am*. 2004; 30:365–80. [PubMed: 15172046]
203. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. *Adv Ther*. 2006; 23:208–17. [PubMed: 16751154]
204. Cohen SB, Woolley JM, Chan W. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. *J Rheumatol*. 2003; 30:225–31. [PubMed: 12563672]
205. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. *Ann Rheum Dis*. 2004; 63:1062–8. [PubMed: 15082469]
206. Pontifex EK, Gerlag DM, Gogarty M, Vinkenoog M, Gibbs A, Burgman I, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy—a single centre, open-label study. *Arthritis Res Ther*. 2011; 13:R7. [PubMed: 21272347]
207. Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). *Clin Rheumatol*. 2011; 29:1169–73. [PubMed: 20532937]
208. Brown C, Toth A, Magnussen R. Clinical benefits of intra-articular anakinra for persistent knee effusion. *J Knee Surg*. 2011; 24:61–5. [PubMed: 21618940]
209. Brown CA, Toth AP, Magnussen B. Clinical benefits of intra-articular anakinra for arthrofibrosis. *Orthopedics*. 2011; 33:877. [PubMed: 21162510]
210. Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT III, et al. Effects of intraarticular IL-1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). *Osteoarthritis Cartilage*. 2012; 20:271–8. [PubMed: 22273632]
211. Chauffier K, London J, Beaudouin C, Fautrel B. Indications of anakinra. *Presse Med*. 2009; 38:799–807. [PubMed: 19278814]
212. Buonomo PS, Bracaglia C, Campana A, El Hachem M, Diociaiuti A, Insalaco A, et al. Relapsing polyarthritides: new therapeutic strategies with biological agents. *Rheumatol Int*. 2011; 30:691–3. [PubMed: 19685056]
213. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polyarthritides: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). *Rheumatology (Oxford)*. 2006; 45:491–2. [PubMed: 16510529]
214. Rech J, Manger B, Lang B, Schett G, Wilhelm M, Birkmann J. Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation. *Rheumatol Int*. 2012; 32:1827–9. [PubMed: 21769488]
215. Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA, Brogan PA. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. *Rheumatology (Oxford)*. 2011; 49:1505–12. [PubMed: 20430869]
216. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. *Ann Rheum Dis*. 2005; 64:296–8. [PubMed: 15208175]
217. Bennett AN, Tan AL, Coates LC, Emery P, Marzo-Ortega H, McGonagle D. Sustained response to anakinra in ankylosing spondylitis. *Rheumatology (Oxford)*. 2008; 47:223–4. [PubMed: 18073250]
218. Tan AL, Marzo-Ortega H, O'Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. *Ann Rheum Dis*. 2004; 63:1041–5. [PubMed: 15066864]
219. So A. Epidemiology: Gout—bad for the heart as well as the joint. *Nat Rev Rheumatol*. 2010; 6:386–7. [PubMed: 20596050]
220. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. *J Clin Rheumatol*. 2013; 19:19–29. [PubMed: 23319019]
221. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. *Arthritis Care Res*. 2013; 65:1381–4.

222. Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1beta blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. *J Clin Rheumatol*. 2012; 18:310–1. [PubMed: 22832289]
223. Molto A, Ea HK, Richette P, Bardin T, Liote F. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. *Joint Bone Spine*. 2012; 79:621–3. [PubMed: 22658375]
224. Ottaviani S, Brunier L, Sibilia J, Maurier F, Ardizzone M, Wendling D, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. *Joint Bone Spine*. 2013; 80:178–82. [PubMed: 23022422]
225. Funck-Brentano T, Salliot C, Leboime A, Zafrani L, Servais A, Larousserie F, et al. First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine. *Rheumatology (Oxford)*. 2011; 50:622–4. [PubMed: 21097448]
226. Ly KH, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais AL. Interleukin-1 blockade in refractory giant cell arteritis. *Joint Bone Spine*. 2013
227. Latourte A, Frazier A, Briere C, Ea HK, Richette P. Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands. *Ann Rheum Dis*. 2013; 72:783–4. [PubMed: 23291388]
228. Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. *Neth J Med*. 2008; 66:489–91. [PubMed: 19075317]
229. Petropoulou AD, Robin M, Socie G, Galicier L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. *Transplantation*. 2011; 90:102–3. [PubMed: 20606570]
230. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. IL-1beta biological treatment of familial Mediterranean fever. *Clinical Rev Allergy Immunol*. 2013; 45:117–30. [PubMed: 23322405]
231. Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in familial Mediterranean fever. *Am J Med Sci*. 2013; 346:137–41. [PubMed: 23276893]
232. Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C, Seve P. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. *Joint Bone Spine*. 2013
233. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist prevents. *Lancet*. 2004; 364:1779–85. [PubMed: 15541451]
234. Metyas SK, Hoffman HM. Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease. *J Rheumatol*. 2006; 33:2085–7. [PubMed: 16981288]
235. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle–Wells syndrome and response to anakinra. *Arthr Rheumat*. 2004; 50:607–12. [PubMed: 14872505]
236. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1 receptor antagonist in the Muckle–Wells syndrome. *N Engl J Med*. 2003; 348:2583–4. [PubMed: 12815153]
237. Rynne M, Maclean C, Bybee A, McDermott MF, Emery P. Hearing improvement in a patient with variant Muckle–Wells syndrome in response to interleukin 1 receptor antagonism. *Ann Rheum Dis*. 2006; 65:533–4. [PubMed: 16531551]
238. Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, Koetter I, Lohse P, Ummerhofer K, et al. Treatment of Muckle–Wells syndrome: analysis of two IL-1-blocking regimens. *Arthritis Res Ther*. 2013; 15:R64. [PubMed: 23718630]
239. Stew BT, Fishpool SJ, Owens D, Quine S. Muckle–Wells syndrome: a treatable cause of congenital sensorineural hearing loss. *B-ENT*. 2013; 9:161–3. [PubMed: 23909124]
240. Sabroe RA, Stokes CA, Parker LC, Higgins K, Prince LR, Sabroe I. Muckle–Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1beta and rapid response to anakinra. *Clin Exp Dermatol*. 2013

241. Enriquez R, Sirvent AE, Padilla S, Noguera-Pons R, Andrada E, Ardoy F, et al. Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome. *Renal Fail.* 2013; 35:738–41.
242. Jeru I, Hentgen V, Normand S, Duquesnoy P, Cochet E, Delwail A, et al. Role of interleukin-1beta in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. *Arthritis Rheum.* 2011; 63:2142–8. [PubMed: 21480187]
243. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. *Arthritis Rheum.* 2005; 52:1283–6. [PubMed: 15818707]
244. Aubert P, Suarez-Farinas M, Mitsui H, Johnson-Huang LM, Harden JL, Pierson KC, et al. Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1beta. *PLOS One.* 2012; 7:e49408. [PubMed: 23226210]
245. Balow JE Jr, Ryan JG, Chae JJ, Booty MG, Bulua A, Stone D, et al. Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts. *Ann Rheum Dis.* 2013; 72:1064–70. [PubMed: 23223423]
246. Kimberley FC, Lobito AA, Siegel RM, Sreaton GR. Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. *Arthritis Res Ther.* 2007; 9:217. [PubMed: 17666110]
247. Andres M, Pascual E. Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. *Ann Rheum Dis.* 2013; 72:155. [PubMed: 22887853]
248. Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G, et al. First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). *PLOS One.* 2013; 8:e73443. [PubMed: 24066048]
249. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. *Am J Physiol Regul Integr Comp Physiol.* 2007; 292:R86–98. [PubMed: 16931648]
250. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. *Br J Dermatol.* 2009; 161:1199–201. [PubMed: 19673875]
251. Dierselhuis MP, Frenkel J, Wulfraat NM, Boelens JJ. Anakinra for flares of pyogenic arthritis in PAPA syndrome. *Rheumatology.* 2005; 44:406–8. [PubMed: 15637033]
252. Schellevis MA, Stoffels M, Hoppenreijns EP, Bodar E, Simon A, van der Meer JW. Variable expression and treatment of PAPA syndrome. *Ann Rheum Dis.* 2011; 70:1168–70. [PubMed: 21325428]
253. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pypin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. *Proc Natl Acad Sci U S A.* 2003; 100:13501–6. [PubMed: 14595024]
254. Demidowich AP, Freeman AF, Kuhns DB, Aksentjevich I, Gallin JI, Turner ML, et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). *Arthritis Rheum.* 2012; 64:2022–7. [PubMed: 22161697]
255. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. *Clin Rev Allergy Immunol.* 2013; 45:202–10. [PubMed: 23334898]
256. Sakran W, Shalev SA, Sakran W, Shalev SA, El-Shanti H, Uziel Y, et al. Chronic recurrent multifocal osteomyelitis and deficiency of interleukin-1-receptor antagonist. *Pediatric Infect Dis J.* 2013; 32:94.
257. Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and

- evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. *Arthritis Rheum.* 2007; 56:3805–13. [PubMed: 17968944]
258. Punzi L, Gava A, Galozzi P, Sfriso P. Miscellaneous non-inflammatory musculoskeletal conditions, Blau syndrome. *Best Pract Res Clin Rheumatol.* 2011; 25:703–14. [PubMed: 22142748]
259. Ruiz Gomez A, Couce ML, Garcia-Villoria J, Torres A, Bana Souto A, Yague J, et al. Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency. *Pediatrics.* 2012; 129:e535–9. [PubMed: 22271696]
260. Herlin T, Fiirgaard B, Bjerre M, Kerndrup G, Hasle H, Bing X, et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. *Ann Rheum Dis.* 2013; 72:410–3. [PubMed: 23087183]
261. Herlin T, Fiirgaard B, Bjerre M, Kerndrup G, Hasle H, Bing X, et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. *Ann Rheum Dis.* 2013; 72:410–3. [PubMed: 23087183]
262. Adam Z, Krejci M, Pour L, Neubauer J, Prasek J, Hajek R. Schnitzler syndrome—report on a fourteen-year course of the disease and an overview of information on the disease. *Vnitr Lek.* 2008; 54:1140–53. [PubMed: 19140523]
263. Cascavilla N, Bisceglia M, D’Arena G. Successful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trial. *Int J Immunopathol Pharmacol.* 2010; 23:633–6. [PubMed: 20646359]
264. Eiling E, Moller M, Kreiselmaier I, Brasch J, Schwarz T. Schnitzler syndrome: treatment failure to rituximab but response to anakinra. *J Am Acad Dermatol.* 2007; 57:361–4. [PubMed: 17467852]
265. Gran JT, Midtvedt O, Haug S, Aukrust P. Treatment of Schnitzler’s syndrome with anakinra: report of three cases and review of the literature. *Scand J Rheumatol.* 2011; 40:74–9. [PubMed: 20936987]
266. Lipsker D. The Schnitzler syndrome. *Orphanet J Rare Dis.* 2010; 5:38. [PubMed: 21143856]
267. Schuster C, Kranke B, Aberer E, Arbab E, Sturm G, Aberer W. Schnitzler syndrome: response to anakinra in two cases and a review of the literature. *Int J Dermatol.* 2009; 48:1190–4. [PubMed: 20064173]
268. Larocca CA, McEvoy JW, Ellis CL, Junkins-Hopkins J, Kolb T, Baer AN, et al. Schnitzler’s syndrome associated with pancreatitis: a disease of IL-1 dysregulation. *Clin Rheumatol.* 2012; 31:169–74. [PubMed: 21710158]
269. Benitez Gutierrez L, Mellor Pita S, Tutor de Ureta P, Yebra Bango M. Schnitzler’s syndrome: a case report and literature review of the response to treatment with anakinra. *Med Clin.* 2013; 140:427–8.
270. Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome—an under diagnosed clinical entity. *Haematologica.* 2013; 98:1581–5. [PubMed: 23812931]
271. Simon A, Asli B, Braun-Falco M, De Koning H, Ferman JP, Grattan C, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. *Allergy.* 2013; 68:562–8. [PubMed: 23480774]
272. Launay D, Dutoit-Lefevre V, Faure E, Robineau O, Hauspie C, Sobanski V, et al. Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. *PLoS One.* 2013; 8:e59327. [PubMed: 23527164]
273. Volz T, Wolbing F, Fischer J, Braun M, Maggoshitz I, Schaller M, et al. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. *Acta Derm Venereol.* 2012; 92:393–4. [PubMed: 22334118]
274. Mesquida M, Molins B, Llorenc V, Hernandez MV, Espinosa G, Dick AD, et al. Current and future treatments for Behcet’s uveitis: road to remission. *Int Ophthalmol.* 2013
275. Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. *Arch Dermatol.* 2006; 142:1591–7. [PubMed: 17178985]
276. Boyer EM, Turman M, O’Neil KM. Partial response to anakinra in life-threatening Henoch–Schonlein purpura: case report. *Pediatr Rheumatol Online J.* 2011; 9:21. [PubMed: 21834965]


277. Paul SM, Hildenbrand H, Jain M, Smith MR, Canna S, Comis L, et al. Functional outcomes of treatment of neonatal onset multisystem inflammatory disease (NOMID) with anakinra. *Arthr Rheumat.* 2005; 52(Suppl):S536.
278. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multi-center series. *Arthritis Rheum.* 2011; 63:545–55. [PubMed: 21280009]
279. Dewitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. *Arthritis Care Res.* 2012; 64:1001–10.
280. Aelion JA, Odhav SK. Prompt response to treatment with anakinra in adult onset Still's disease. *Ann Rheum Dis.* 2004; 63(Suppl 1):265. abs.
281. Haraoui B, Bourrelle D, Kaminska E. Anakinra in the treatment of adult onset Still's disease. *Ann Rheum Dis.* 2004; 63(Suppl 1):263. abs.
282. Lahiri M, Teng GG. A case of refractory adult-onset Still's disease treated with anakinra. *Int J Rheum Dis.* 2010; 13:e36–41. [PubMed: 20704609]
283. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. *Arthritis Res Ther.* 2011; 13:R91. [PubMed: 21682863]
284. Moulis G, Sailler L, Astudillo L, Pignet G, Arlet P. May anakinra be used earlier in adult onset Still disease? *Clin Rheumatol.* 2010; 29:1199–200. [PubMed: 20428907]
285. Mylona E, Goulinopoulou S, Samarkos M, Fanourgiakis P, Papadakos V, Skoutelis A. Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra. *Clin Rheumatol.* 2008; 27:659–61. [PubMed: 18095015]
286. Raffaeiner B, Botsios C, Dinarello CA, Ometto F, Punzi L, Ramonda R. Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. *Joint Bone Spine.* 2011; 78:100–1. [PubMed: 21036649]
287. Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset Still's disease with anakinra. *J Clin Rheumatol.* 2003; 9:330–2. [PubMed: 17041487]
288. Tamaki H, Shimizu H, Hiraoka E, Uechi E, Kishimoto M, Yamaguchi K, et al. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease. *Mod Rheumatol.* 2010; 20:200–4. [PubMed: 20037747]
289. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. *Ann Rheum Dis.* 2005; 64:647–8. [PubMed: 15374853]
290. Vordenbaumen S, Ostendorf B, Sander O, Richter J, Schneider M. Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease. *Ann Rheum Dis.* 2009; 68:450–1. [PubMed: 19213754]
291. Youssef J, Lazaro E, Blanco P, Viallard JF. Blockade of interleukin 1 receptor in Still's disease affects activation of peripheral T-lymphocytes. *J Rheumatol.* 2008; 35:2453–6. [PubMed: 19143047]
292. Woo P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. *Ann Rheum Dis.* 2008; 67:281–2. [PubMed: 18292104]
293. Teran A, Casafont F, Fabrega E, Martinez-Taboada VM, Rodriguez-Valverde V, Pons-Romero F. Adult-onset Still's disease with liver failure requiring liver transplantation. *Gastroenterol Hepatol.* 2009; 32:681–6. [PubMed: 19783075]
294. Rinkin C, Van Durme C, Fautrel B, Malaise M. A rare case of arthritis and fever. *Rev Med Liege.* 2013; 68:423–7. [PubMed: 24053103]
295. Iliou C, Papagoras C, Tsifetaki N, Voulgari PV, Drosos AA. Adult-onset Still's disease: clinical, serological and therapeutic considerations. *Clin Exp Rheumatol.* 2013; 31:47–52. [PubMed: 23010097]
296. Jaqua NT, Finger D, Hawley JS. Adult-onset Still's disease masquerading as sepsis in an asplenic active duty soldier. *Case Rep Med.* 2012; 2012:349521. [PubMed: 23251171]

297. Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. *Arthritis Care Res.* 2013; 65:822–6.
298. Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. *J Rheumatol.* 2011; 37:879–80. [PubMed: 20360206]
299. Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. *J Rheumatol.* 2006; 33:2081–4. [PubMed: 17014024]
300. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. *J Clin Rheumatol.* 2011; 17:23–7. [PubMed: 21169853]
301. Aronson IK, Worobec SM. Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. *Dermatol Ther.* 2010; 23:389–402. [PubMed: 20666826]
302. Chou RC, Dinarello CA, Ferry JA, Dal Cin P. A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia. *Arthritis Care Res.* 2010; 62:137–40.
303. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. *Nat Clin Pract Rheumatol.* 2008; 4:615–20. [PubMed: 18825135]
304. Loh NK, Lucas M, Fernandez S, Prentice D. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. *Int Med J.* 2012; 42:1358–62.
305. Kahn PJ, Cron RQ. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. *J Rheumatol.* 2013; 40:743–4. [PubMed: 23637382]
306. Butin M, Mekki Y, Phan A, Billaud G, Di Filippo S, Javouhey E, et al. Successful immunotherapy in life-threatening parvovirus B19 infection in a child. *Pediatric Infect Dis J.* 2013; 32:789–92.
307. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. *Genes Immun.* 2012; 13:289–98. [PubMed: 22418018]
308. Delluc A, Limal N, Puechal X, Frances C, Piette JC, Cacoub P. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. *Ann Rheum Dis.* 2008; 67:278–9. [PubMed: 18192308]
309. Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet's syndrome. *Dermatology.* 2011; 222:123–7. [PubMed: 21464561]
310. Belani H, Gensler L, Bajpai U, Meinhardt E, Graf J, Pincus L, et al. Neutrophilic urticaria with systemic inflammation: a case series. *JAMA Dermatol.* 2013; 149:453–8. [PubMed: 23715523]
311. Lipsker D, Perrigouard C, Foubert A, Cribier B. Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophil-mediated inflammatory skin disease. *Dermatology.* 2010; 220:264–7. [PubMed: 20197651]
312. Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. *Blood.* 2010; 116:4070–6. [PubMed: 20724540]
313. Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim–Chester disease by interleukin-1 receptor antagonist protein. *Joint Bone Spine.* 2013
314. Aubert O, Aouba A, Deshayes S, Georgin-Lavialle S, Rieu P, Hermine O. Favorable radiological outcome of skeletal Erdheim–Chester disease involvement with anakinra. *Joint Bone Spine.* 2013; 80:206–7. [PubMed: 22999905]
315. Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. *Ann Rheum Dis.* 2012; 71:1098–100. [PubMed: 22219141]
316. Stojanov S, Lapidus S, Chitkara P, Feder H, Salazar JC, Fleisher TA, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. *Proc Natl Acad Sci U S A.* 2011; 108:7148–53. [PubMed: 21478439]

317. Cantarini L, Lucherini OM, Cimaz R, Rigante D, Baldari CT, Laghi Pasini F, et al. Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. *Rheumatol Int.* 2012; 32:4015–8. [PubMed: 20473499]
318. Galeotti C, Tran T-A, Franchi-Abella S, Fabre M, Pariente D, Kone-Paut I. IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease. *J Pediatr Hematol Oncol.* 2008; 30:920–4. [PubMed: 19131781]
319. Sparsa L, Afif N, Goetz J, Sordet C, Chatelus E, Lipsker D, et al. Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus? *Rheumatol Int.* 2012; 31:255–8. [PubMed: 19823837]
320. Cohen S, Tacke CE, Straver B, Meijer N, Kuipers IM, Kuijpers TW. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. *Ann Rheum Dis.* 2012; 71:2059–61. [PubMed: 22689319]
321. Demin I, Hamren B, Luttringer O, Pillai G, Jung T. Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. *Clin Pharmacol Ther.* 2012; 92:352–9. [PubMed: 22760002]
322. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. *Diabetes Metab.* 2013
323. Rissanen A, Howard CP, Botha J, Thuren T. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. *Diabetes Obes Metab.* 2012
324. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulfraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. *N Engl J Med.* 2012; 367:2396–406. [PubMed: 23252526]
325. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. *Ann Rheum Dis.* 2012; 71:1839–48. [PubMed: 22586173]
326. Hacıhamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. *Rheumatology (Oxford).* 2012; 51:1041. [PubMed: 22403182]
327. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. *Ann Rheum Dis.* 2011; 70:1347–8. [PubMed: 21345814]
328. Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. *Ann Intern Med.* 2012; 156:907–8. [PubMed: 22711098]
329. Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Behcet's disease. *Clin Exp Rheumatol.* 2012; 30:S115. [PubMed: 22776542]
330. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease. *Ann Rheum Dis.* 2012; 71:1589–91. [PubMed: 22586166]
331. Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. *Arthritis Res Ther.* 2013; 15:R33. [PubMed: 23442610]
332. Imagawa T, Nishikomori R, Takada H, Takeshita S, Patel N, Kim D, et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). *Clin Exp Rheumatol.* 2013; 31:302–9. [PubMed: 23380020]
333. Ozen S. Familial mediterranean fever: revisiting an ancient disease. *Eur J Pediatr.* 2003; 162:449–54. [PubMed: 12751000]
334. de Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JW, Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. *Ann Rheum Dis.* 2013; 72:1634–8. [PubMed: 23087179]

335. Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. *Semin Arthritis Rheum*. 2013; 42:413–6. [PubMed: 22901459]
336. Kolly, L.; Karababa, M.; Joosten, LA. Inflammatory role of ASC. 2009.
337. Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B, Pillet P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. *Rheumatology (Oxford)*. 2012; 51:1855–9. [PubMed: 22740624]
338. Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. *JAMA Dermatol*. 2013; 149:209–15. [PubMed: 23426477]
339. Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V, et al. Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. *Arthritis Rheum*. 2013; 65:513–8. [PubMed: 23124805]
340. Tsitsami E, Papadopoulou C, Speletas M. A case of hyperimmunoglobulinemia d syndrome successfully treated with canakinumab. *Case Rep Rheumatol*. 2013; 2013:795027. [PubMed: 23691418]
341. Church LD, Savic S, McDermott MF. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap). *Biologics: Targets Ther*. 2008; 2:733–42.
342. Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). *J Inflamm Res*. 2010; 3:1–8. [PubMed: 22096352]
343. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. *Arthritis Rheum*. 2008; 58:2432–42. [PubMed: 18668591]
344. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. *Ann Intern Med*. 2012; 157:533–41. [PubMed: 23070486]
345. Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. *Clin Ther*. 2012; 34:2091–103. [PubMed: 23031624]
346. Hoffman HM. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). *Expert Opin Biol Ther*. 2009; 9:519–31. [PubMed: 19344287]
347. Kapur S, Bonk ME. Rilonacept (arcylast), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. *Pharm Ther*. 2009; 34:138–41.
348. Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. *Allergy*. 2012; 67:943–50. [PubMed: 22583335]
349. Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. *Arthritis Rheum*. 2013; 65:2486–96. [PubMed: 23754188]
350. Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. *Rheumatology (Oxford)*. 2013; 52:1285–92. [PubMed: 23485476]
351. Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. *Arthritis Care Res*. 2012; 64:1462–70.
352. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. *Arthritis Res Ther*. 2013; 15:R25. [PubMed: 23375025]
353. Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. *Ann Rheum Dis*. 2012; 71:2056–7. [PubMed: 22679302]

354. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. *Nat Med.* 2007; 13:851–6. [PubMed: 17572686]

**Fig. 1.**

Time line for milestones in clinical applications with IL-1 blocking therapeutics. HIDS, hyper IgD syndrome; CAPS, cryopyrin associated periodic syndromes; FMF, familial Mediterranean fever; TRAPS, TNF receptor associated periodic syndrome; MWS, Muckle–Wells syndrome; AOSD, adult onset Still disease; SJIA, systemic juvenile idiopathic arthritis; STEMI, ST segment elevated my myocardial infarction.




Fig. 2. Role of IL-1 α and IL-1 β in sterile inflammation. **Event 1.** With hypoxic damage in the necrotic area, dying cells lose membrane integrity. **Event 2.** With cellular necrosis, cell contents are released including the active IL-1 α precursor [354]. Anti-IL-1 α antibodies neutralize IL-1 α at this step. **Event 3.** The IL-1 α precursor binds to IL-1R1 on nearby resident macrophages; anakinra and anti-IL-1R1 antibodies prevent this event. With binding of the IL-1 α precursor to the IL-1R1, synthesis of IL-1 β precursor takes place, caspase-1 cleaves the precursor releasing active IL-1 β . Anti-IL-1 β blocks at this step. Triggered by IL-1 α binding to the IL-1R1 on resident macrophages, chemokines are also released. **Event 4.** IL-1 β activates capillaries in the ischemic tissues to express the intracellular adhesion molecule-1 (ICAM-1). Circulating blood neutrophils roll on the endothelium, adhere to ICAM-1 and enter the ischemic tissue via diapedesis [6]. Anakinra or anti-IL-1R1 prevents this event. **Event 5.** With resident macrophages releasing chemokines, a chemokine gradient forms, which facilitates the passage to blood neutrophils into the ischemic area. **Event 6.** The number of neutrophils increases into the area of the ischemic event and local IL-1 prolongs the survival of neutrophils at this step. **Event 7.** Neutrophils scavenge dying cells and release proteases that contribute to the destruction of penumbral cells.

Table 1

Anakinra treatment for joint, bone and muscle diseases.

Rheumatoid arthritis	[62–65,181,182,191–205]
Psoriatic arthritis	[206,207]
Osteoarthritis	[83,84]
Erosive osteoarthritis of the hand	[82]
Arthrofibrosis/traumatic knee injury	[208,209]
Anterior cruciate knee ligament tear	[210]
Relapsing polychondritis	[211–213]
chronic recurrent multifocal osteomyelitis	[214,215]
Ankylosing spondylitis	[216–218]
Gout and pseudogout	[69–72,74,77,219–221]
Calcium pyrophosphate arthritis	[222–224]
Gout of the lumbar spine	[225]
Antisynthetase syndrome	[140]
Idiopathic inflammatory myopathies	[226]
Hemochromatosis-related arthritis of the hands	[227]

Table 2

Hereditary systemic inflammatory diseases treated with anakinra.

Familial Mediterranean fever (FMF)	[87–93,160,228–232]
FCAS	[107,233] [234]
Muckle–Wells syndrome	[14,115,124,235–241]
NLRP12 autoinflammatory syndrome	[242]
NOMID	[14,15,39,151–153,243–245]
TRAPS	[118–121,246–248]
HIDS	[96,98–100,102,249]
PAPA	[147,185,250–254]
PASH	[185,255]
DIRA	[1,2,256]
Blau syndrome/granulomatous arthritis	[257,258]
Mevalonate kinase deficiency	[259]
Majeed syndrome	[260,261]

Table 3

Systemic and local inflammatory diseases.

Schnitzler syndrome	[134,135,138,262–273]
Behçet disease	[140,160,274]
secondary amyloidosis	[89,91,124,138,154,159–162,275]
Henoch–Schonlein purpura	[276]
Idiopathic recurrent pericarditis	[121–124,164,165,167]
Systemic-onset juvenile idiopathic arthritis	[13,16,126,151,153,154,277–279]
Adult onset Still disease	[127–131,280–297]
Macrophage activation syndrome	[298–307]
Sweet's syndrome/neutrophilic dermatoses	[147,308–310]
Neutrophilic panniculitis	[299,301,311]
Erdheim–Chester/histiocytoses	[312–314]
SAPHO	[17,215,315]
PFAPA	[316,317]
Multicentric Castleman disease	[318]
Jessner–Kanof disease	[319]
Primary Sjogren syndrome fatigue	[54]
Kawasaki disease	[320]
Colitis in chronic granulomatous disease	[178]

Table 4

Common diseases (non-arthritic) responsive to anakinra.

Post-myocardial infarction cardiac remodeling	[28,29]
Systolic heart failure	[30]
Diastolic heart failure	[34]
Smoldering myeloma	[176]
Cerebrovascular accident	[26]
Hidradenitis suppurativa	[146,185–187]
Type 2 diabetes	[48,49]
Type 1 diabetes	[37]
Metabolic syndrome	[44]
Giant cell arteritis	[143]
Dry eye disease	[142]

Table 5Treatment of inflammatory diseases with anti-IL-1 β monoclonal antibodies.

	References
Canakinumab	
Rheumatoid arthritis	[68,321]
Type 2 diabetes	[60,322,323]
SJIA	[133,324]
Refractory gout	[73,78,79,325]
FMF	[231,326,327]
TRAPS	[328]
Behcet's	[329,330]
CAPS	[111–113,155,331–333]
Schnitzler's syndrome	[334,335]
AOSD	[336]
MKD	[337]
PAPA	[338]
Majeed syndrome	[260]
Blau syndrome	[339]
HIDS	[340]
Gevokizumab	
Type 2 diabetes	[50]
Behcet's disease	[141]
Fatigue in Type 2 diabetes	[53]
LY2189102	[52]

Table 6

Riloncept therapies for inflammatory diseases.

Condition	References
CAPS	[341–343]
FMF	[108,344–347]
Schnitzler's syndrome	[348]
SJIA	[349]
Gout	[75,350–352]
AOSD	[353]